Imperial College London
Alternate

Dr Lionel Tan

Faculty of Medicine, Department of Infectious Disease

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

+44 (0)20 3313 2065lionel.tan

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Tan:2008:10.2217/17469600.2.2.111,
author = {Tan, LK and Nelson, M},
doi = {10.2217/17469600.2.2.111},
journal = {Future HIV therapy},
pages = {111--123},
title = {Maraviroc: a CCR5 antagonist},
url = {http://dx.doi.org/10.2217/17469600.2.2.111},
volume = {2},
year = {2008}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - HIV requires binding to both the CD4 molecule and a coreceptor to enable entry into the cell. CCR5 is a chemokine receptor that is utilized as a coreceptor by the majority of virus in early asymptomatic HIV infection. Maraviroc is a novel small molecule CCR5 antagonist which, in Phase IIb/III clinical trials up to 48 weeks, has been shown to be efficacious as part of an optimized antiretroviral regimen against CCR5 tropic HIV-1 in treatment-experienced patients. A further trial has demonstrated its noninferiority to efavirenz in achieving a HIV viral load less than 400 copies/ml as part of highly active antiretroviral therapy in treatment-naive individuals. It has recently received regulatory approval for use in North America and Europe in treatment-experienced patients. With increasing use, the role of maraviroc in the treatment of HIV-infected patients will be more clearly defined.
AU  - Tan,LK
AU  - Nelson,M
DO  - 10.2217/17469600.2.2.111
EP  - 123
PY  - 2008///
SP  - 111
TI  - Maraviroc: a CCR5 antagonist
T2  - Future HIV therapy
UR  - http://dx.doi.org/10.2217/17469600.2.2.111
UR  - http://www.futuremedicine.com/loi/fht
VL  - 2
ER  -
Download